5 research outputs found
Distribution of NHBA peptides in the 300 isolates panel.
<p>Others<sup>a</sup>: NHBA peptides not present in more than one isolate (peptides 8, 9, 13, 25, 47, 53, 115, 160, 187, 237, 304, 307, 308, 309, 310, 355, 367, 368, 370, 385, 460, 461, 462, 463, 464, 465, 468, 469, 470, 471). Others cc<sup>b</sup>: Others clonal complexes. NA<sup>c</sup>: Clonal complexes non assigned.</p
Distribution of clonal complexes and main PorA genotypes in the 300 isolates panel.
<p>*NA: Clonal complex non assigned.</p
Distribution of NadA variants and peptides in the 300 isolates panel.
<p>Frameshift<sup>1</sup>: The <i>nadA</i> nucleotide allele presents a frameshift mutation resulting in a premature stop codon (variant 1 allele 44; variant 4/5 alleles 12, 34, 38, 39, 40 and 46; variant 6 alleles 37, 43 and 94). IS1301<sup>2</sup>: The <i>nadA</i> gene (allele 50) is disrupted by an insertion sequence IS1301. NA<sup>3</sup>: Clonal complex non assigned.</p
Distribution of MATS strains predicted to be covered by cc and specific vaccine antigen combinations.
<p>Strains were defined as covered if they possessed PorA P1.4 or had relative potency greater than the positive bactericidal threshold for fHbp, NHBA or NadA. *NA: Clonal complex non assigned.</p
Distribution of fHbp variant families and peptides in the 300 isolates panel.
<p>Others<sup>1</sup>: FHbp variant family 1 peptides not present in more than three isolates (peptides 4, 15, 35, 37, 54, 65, 90, 87, 108, 110, 144, 213, 218, 236, 252,275, 322, 357, 358, 359, 360, 361, 362, 363, 365, 373, 374, 403, 456, 480, 544, 545). Others<sup>2</sup>: FHbp variant family 2 peptides not present in more than three isolates (peptides 18, 24, 34, 104, 367, 548, 551). Others<sup>3</sup>: FHbp variant family 3 peptides not present in more than three isolates (peptides 29, 31, 174, 188, 294, 364, 366, 368, 398, 399, 400,401,402, 485, 494, 532, 536, 549, 550, 552, 555). Others cc*: Others clonal complexes, included clonal complexes non assigned.</p